The summit featured cutting-edge discussions on ageing research, with Alex Zhavoronkov’s keynote being a highlight. He detailed Insilico Medicine’s AI-based approach to drug discovery and its implications for longevity. His talk demonstrated the tangible progress being made in bringing AI-generated drugs into clinical use, offering hope for future breakthroughs in age-related diseases and life extension.

Key Points:

• AI in Drug Discovery: Zhavoronkov highlighted how AI is transforming drug discovery by analysing vast amounts of biological data to identify new therapeutic targets and create drugs more efficiently.
• Dual-Purpose Therapeutics: A key focus was on "dual-purpose therapeutics"—drugs aimed at both specific diseases and broader anti-ageing effects, addressing multiple hallmarks of ageing.
• Generative Chemistry: Insilico Medicine uses generative AI to design novel molecules, optimizing them for specific medical applications. AI's ability to learn across disciplines is making the drug development process faster and more precise.
• Phase 2 Trials: Insilico’s AI-generated drugs are already in human trials, with seven clinical trials in progress, including two in Phase 2. This marks a major step forward in AI-driven medicine.
• Global Impact: The company has a strong global presence, with operations in the U.S., Asia, and the Middle East. It’s collaborating with top pharmaceutical companies to expand the use of AI in medicine.
• Future of AI in Biotech: Zhavoronkov discussed the potential of quantum computing and multimodal AI models to further enhance the drug discovery process, predicting breakthroughs in generating synthetic data and developing new therapies.